Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Hematopoietic stem cell–derived Tregs are essential for maintaining favorable B cell lymphopoiesis following posttransplant cyclophosphamide
Yuichi Sumii, Takumi Kondo, Shuntaro Ikegawa, Takuya Fukumi, Miki Iwamoto, Midori Filiz Nishimura, Hiroyuki Sugiura, Yasuhisa Sando, Makoto Nakamura, Yusuke Meguri, Takashi Matsushita, Naoki Tanimine, Maiko Kimura, Noboru Asada, Daisuke Ennishi, Yoshinobu Maeda, Ken-ichi Matsuoka
Yuichi Sumii, Takumi Kondo, Shuntaro Ikegawa, Takuya Fukumi, Miki Iwamoto, Midori Filiz Nishimura, Hiroyuki Sugiura, Yasuhisa Sando, Makoto Nakamura, Yusuke Meguri, Takashi Matsushita, Naoki Tanimine, Maiko Kimura, Noboru Asada, Daisuke Ennishi, Yoshinobu Maeda, Ken-ichi Matsuoka
View: Text | PDF
Research Article Hematology Transplantation

Hematopoietic stem cell–derived Tregs are essential for maintaining favorable B cell lymphopoiesis following posttransplant cyclophosphamide

  • Text
  • PDF
Abstract

Posttransplant cyclophosphamide (PTCy) is associated with a low incidence of chronic graft-versus-host disease (cGVHD) following hematopoietic stem cell (HSC) transplantation. Previous studies have shown the important roles of B cell immunity in cGVHD development. Here, we investigated the long-term reconstitution of B lymphopoiesis after PTCy using murine models. We first demonstrated that the immune homeostatic abnormality leading to cGVHD is characterized by an initial increase in effector T cells in the bone marrow and subsequent B and Treg cytopenia. PTCy, but not cyclosporine A or rapamycin, inhibits the initial alloreactive T cell response, which restores intra-bone marrow B lymphogenesis with a concomitant vigorous increase in Tregs. This leads to profound changes in posttransplant B cell homeostasis, including decreased B cell activating factors, increased transitional and regulatory B cells, and decreased germinal center B cells. To identify the cells responsible for PTCy-induced B cell tolerance, we selectively depleted Treg populations that were graft or HSC derived using DEREG mice. Deletion of either Treg population without PTCy resulted in critical B cytopenia. PTCy rescued B lymphopoiesis from graft-derived Treg deletion. In contrast, the negative effect of HSC-derived Treg deletion could not be overcome by PTCy, indicating that HSC-derived Tregs are essential for maintaining favorable B lymphopoiesis following PTCy. These findings define the mechanisms by which PTCy restores homeostasis of the B cell lineage and reestablishes immune tolerance.

Authors

Yuichi Sumii, Takumi Kondo, Shuntaro Ikegawa, Takuya Fukumi, Miki Iwamoto, Midori Filiz Nishimura, Hiroyuki Sugiura, Yasuhisa Sando, Makoto Nakamura, Yusuke Meguri, Takashi Matsushita, Naoki Tanimine, Maiko Kimura, Noboru Asada, Daisuke Ennishi, Yoshinobu Maeda, Ken-ichi Matsuoka

×

Figure 4

Decreased BAFF levels and germinal center B cells and increased IL-10–producing regulatory B cells are accompanied by B lymphopoiesis promotion after PTCy.

Options: View larger image (or click on image) Download as PowerPoint
Decreased BAFF levels and germinal center B cells and increased IL-10–pr...
Lethally irradiated (10 Gy) BDF1 recipients (H2Kb/dCD45.2+) received transplants of 5 × 106 Ly 5.1 B6 (H2Kb/bCD45.1+) splenocytes and 5 × 106 B6 (H2Kb/bCD45.2+) TCD-BM cells. The syngeneic group was administered the same numbers of splenocytes and TCD-BM cells from the BDF1 mice. All the recipient mice were injected intraperitoneally with 50 mg/kg cyclophosphamide or vehicle on day 3 after BMT. (A) Serum levels of BAFF on days 56 (syngeneic/vehicle-treated, n = 4; syngeneic/PTCy-treated, n = 4; allogeneic/vehicle-treated, n = 5; and allogeneic/PTCy-treated, n = 4) and 84 (syngeneic/vehicle-treated, n = 5; syngeneic/PTCy-treated, n = 5; allogeneic/vehicle-treated, n = 7; and allogeneic/PTCy-treated, n = 5) after BMT (data derived from 2 independent experiments). (B) BAFF per HSC-derived B220+ cell on day 56 (allogeneic/vehicle-treated, n = 5, and allogeneic/PTCy-treated, n = 4) and 84 (allogeneic/vehicle-treated, n = 7, and allogeneic/PTCy-treated, n = 5) after allogeneic BMT (data derived from 2 independent experiments). (C) Representative flow cytometry plots identifying GC B (B220+GL7+Fas+) cells and the frequency of GC B cells in the lymph nodes on day 56 after allogeneic BMT (allogeneic/vehicle-treated, n = 7; allogeneic/PTCy-treated, n = 7; and data derived from 2 independent experiments). (D) Representative flow cytometry plots identifying IL-10–producing Bregs in splenic marginal zone B cell (CD19+CD21hiCD23−CD24int) population, and the number of Bregs in marginal zone B cell population on day 56 following BMT (syngeneic/vehicle-treated, n = 4; syngeneic/PTCy-treated, n = 4; allogeneic/vehicle-treated, n = 7; allogeneic/PTCy-treated, n = 7; and data derived from 1 experiment). Bregs in the syngeneic and allogeneic groups were defined as CD19+IL-10+H2Kd+CD45.1− and CD19+IL-10+H2Kd−CD45.1− gated cells, respectively. Data are expressed as the mean ± SEM. P values were determined using the Kruskal-Wallis test (A and D) and the Mann-Whitney U test (B and C). *P < 0.05, **P < 0.01, ***P < 0.001. GC, germinal center; Breg, regulatory B cell.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts